Bristol Myers Squibb appointed Chris Shibutani, M.D., formerly a senior biotech analyst at Goldman Sachs, as EVP and chief strategy officer. Shibutani combines clinical experience as an anesthesiologist with financial expertise, positioning him to shape BMS's long-term approach to partnerships and collaborations. This move parallels recent Big Pharma trends of recruiting industry analysts with medical backgrounds to strengthen strategic direction, as seen by Novartis and Pfizer's similar hires.